Helix BioPharma Corp. Reports Fiscal Year 2026 Financial Results and Provides Corporate and Clinical Updates

Vancouver, British Columbia — October 29, 2026 — Leads & Copy — Helix BioPharma Corp., a clinical-stage oncology company, announced its financial results for the fiscal year ended July 31, 2026, reporting a net loss of $3,354,000, or $0.04 per common share, an improvement from a net loss of $5,205,000, or $0.09 per common share, in the prior fiscal year. The company also provided updates on its clinical development and corporate activities.

Key developments during fiscal 2026 and subsequent to year-end include significant leadership appointments. On August 17, 2026, Markus Loeffler, MD, MBA, was appointed Chief Medical Officer, bringing over 30 years of oncology drug development experience. Helen Middleton was appointed General Counsel and David Browning was appointed Vice President of Clinical Operations on June 30, 2026, both with over 30 years of experience in their respective fields.

In clinical development, the company announced the presentation of data from its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference on February 24, 2026. The presentation highlighted the therapeutic potential of CEACAM6 across multiple epithelial cancers.

On February 5, 2026, Helix BioPharma extended its Research and Exclusive Option Agreement with metaShape Pharma AG for LEUMUNA™ through December 31, 2028. metaShape is developing the compound, MS 001, for adipose tissue-related and metabolic diseases.

Earlier corporate developments include the appointment of Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt to the Board of Directors on September 28, 2026, with Ms. Krumeich assuming the role of Chair. Thomas Mehrling, MD, PhD, was appointed CEO and a director on August 14, 2026.

In May 2026, the company issued unsecured convertible debentures with an aggregate principal of $3,673,000, bearing interest at 25% per annum and maturing on July 27, 2027. These debentures are convertible at the holder’s option at maturity. The company also announced the grant of 1,297,000 incentive stock options and the cancellation of 2,200,000 previously granted options.

Research and Development expenses decreased by 54% to $1,620,000 for the year ended July 31, 2026, compared to $3,558,000 in the previous year. This reduction was attributed to the wind-down of previous clinical development activities and deferral of external service provider engagement pending fundraising. Operating, General and Administration expenses increased by 10% to $2,019,000, primarily due to higher stock-based compensation expenses related to stock option grants and increased salaries.

As of July 31, 2026, the company had cash reserves of $804,000, which are insufficient to meet anticipated working capital and capital expenditure requirements for the next twelve months. Management considers securing additional funds, primarily through equity arrangements, to be of utmost importance. The company is evaluating financing alternatives, including bridge financing and a subsequent larger financing to fund future clinical development stages.

Helix BioPharma Corp. is developing therapies for difficult-to-treat cancers, with its pipeline including L-DOS47 for non-small cell lung cancer, LEUMUNA™ for post-transplant leukemia relapse, and GEMCEDA™ for advanced solid tumors. The company's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0).

Source: Helix BioPharma Corp.